<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Syphilis: Treatment and monitoring</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Syphilis: Treatment and monitoring</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Syphilis: Treatment and monitoring</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Charles B Hicks, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Meredith Clement, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeanne Marrazzo, MD, MPH, FACP, FIDSA</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Mitty, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 21, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Syphilis is an infection caused by the bacterium <em>Treponema pallidum</em>. During the initial phase of infection, the organism disseminates widely, setting the stage for subsequent manifestations. If untreated, syphilis can have a number of significant late adverse outcomes including cardiovascular, gummatous, and neurologic complications. The management of syphilis is based upon its classification into stages of disease: early syphilis (includes primary, secondary, and early latent syphilis); late (includes late latent, cardiovascular, and gummatous syphilis); and neurosyphilis (includes central nervous system disease and ocular syphilis at any time).</p><p>The treatment of syphilis in nonpregnant adults and patient monitoring after treatment will be reviewed here. Other topics related to the treatment of syphilis are discussed elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7588.html" rel="external">"Syphilis: Screening and diagnostic testing"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7584.html" rel="external">"Syphilis: Epidemiology, pathophysiology, and clinical manifestations in patients without HIV"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7599.html" rel="external">"Neurosyphilis"</a>.) </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7600.html" rel="external">"Syphilis in patients with HIV"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4794.html" rel="external">"Syphilis in pregnancy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14428.html" rel="external">"Congenital syphilis: Clinical manifestations, evaluation, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15400.html" rel="external">"Congenital syphilis: Management and outcome"</a>.)</p><p></p><p class="headingAnchor" id="H2782145010"><span class="h1">GENERAL APPROACH TO ANTIMICROBIAL THERAPY</span><span class="headingEndMark"> — </span>Our approach to the treatment of nonpregnant adults with syphilis are consistent with the 2021 guidelines from the United States Centers for Disease Control and Prevention (CDC) [<a href="#rid1">1</a>]. Discussions of the treatment of syphilis in the setting of HIV infection and pregnancy, as well as congenital syphilis, are found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7600.html" rel="external">"Syphilis in patients with HIV"</a> and  <a class="medical medical_review" href="/z/d/html/15400.html" rel="external">"Congenital syphilis: Management and outcome"</a> and  <a class="medical medical_review" href="/z/d/html/4794.html" rel="external">"Syphilis in pregnancy", section on 'Maternal treatment'</a>.)</p><p class="headingAnchor" id="H4065348473"><span class="h2">Pretreatment evaluation</span><span class="headingEndMark"> — </span>Patients with signs and symptoms consistent with syphilis should undergo serologic testing to confirm the diagnosis. However, certain groups of patients can be treated empirically for early syphilis based upon clinical findings (eg, patients with a suspected chancre) or a known recent exposure. (See  <a class="medical medical_review" href="/z/d/html/7584.html" rel="external">"Syphilis: Epidemiology, pathophysiology, and clinical manifestations in patients without HIV", section on 'Primary syphilis (chancre)'</a> and <a class="local">'Treatment of early syphilis'</a> below and <a class="local">'Treatment after an exposure'</a> below.)</p><p>A nontreponemal serologic test should be obtained just before initiating therapy (ideally on the first day of treatment) to establish the pretreatment titer. Since nontreponemal titers can increase significantly between the date of diagnosis and the date of treatment, this test is critical to establishing the adequacy of the post-treatment serologic response. (See  <a class="medical medical_review" href="/z/d/html/7588.html" rel="external">"Syphilis: Screening and diagnostic testing", section on 'Serologic tests'</a> and <a class="local">'Patient monitoring'</a> below.)</p><p>We also evaluate patients with syphilis for other sexually transmitted infections (STIs)  (<a class="graphic graphic_table graphicRef103391" href="/z/d/graphic/103391.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/7596.html" rel="external">"Screening for sexually transmitted infections"</a>.)</p><p class="headingAnchor" id="H783159402"><span class="h2">Penicillin as the treatment of choice</span><span class="headingEndMark"> — </span>Parenterally-delivered penicillin G is the treatment of choice for all stages of syphilis  (<a class="graphic graphic_table graphicRef50435" href="/z/d/graphic/50435.html" rel="external">table 2</a>) [<a href="#rid2">2</a>]. Treatment recommendations are based upon the pharmacokinetics of the available drugs, the microbe's slow growth rate (penicillin is active against dividing organisms and requires prolonged antimicrobial exposure for effective killing), the in vitro activity of antimicrobial agents against <em>T. pallidum</em>, and more than 50 years of clinical experience [<a href="#rid1">1,3</a>].</p><p>In all types of syphilis, prolonged continuous levels of penicillin are necessary for the elimination of treponemes [<a href="#rid4">4</a>]. However, the dosage, formulation, and duration of treatment depend upon the stage of disease and whether or not infection involves "protected sites" that sequester <em>T. pallidum </em>(eg, ocular structures, the central nervous system)  (<a class="graphic graphic_table graphicRef50435" href="/z/d/graphic/50435.html" rel="external">table 2</a>). As an example, long-acting <a class="drug drug_general" data-topicid="9551" href="/z/d/drug information/9551.html" rel="external">penicillin G benzathine</a> given intramuscularly (IM; standard treatment of early syphilis) provides continuous levels of penicillin in all tissues except these protected sites. Thus, patients with syphilis involving these areas should be treated with intravenous (IV) <a class="drug drug_general" data-topicid="9749" href="/z/d/drug information/9749.html" rel="external">penicillin G</a>. (See <a class="local">'Treatment of neuro/ocular/otic syphilis'</a> below.)</p><p>For patients without neurosyphilis, the appropriate formulation of parenteral penicillin is <a class="drug drug_general" data-topicid="9551" href="/z/d/drug information/9551.html" rel="external">penicillin G benzathine</a>, which is marketed under the trade name Bicillin L-A. This agent should only be given via the IM route since IV administration has been associated with cardiopulmonary arrest and death [<a href="#rid4">4</a>]. IM administration of penicillin G benzathine produces detectable serum concentrations for up to 30 days.</p><p>Bicillin L-A must be distinguished from Bicillin C-R (which contains equal concentrations of procaine and <a class="drug drug_general" data-topicid="9551" href="/z/d/drug information/9551.html" rel="external">benzathine penicillin</a>), which should <strong>not</strong> be used to treat patients with syphilis. Bicillin C-R results in detectable serum drug levels for only seven days. Inadvertent use of this shorter-acting preparation in a Los Angeles sexually transmitted disease clinic led to a large-scale public health investigation and retesting and retreatment of a significant number of patients [<a href="#rid5">5</a>]. The Bicillin C-R product is now labeled with a warning: "not for the treatment of syphilis." This agent is typically used for the treatment of susceptible streptococci. (See  <a class="medical medical_review" href="/z/d/html/8049.html" rel="external">"Treatment and prevention of streptococcal pharyngitis in adults and children", section on 'Antibiotic treatment'</a>.)</p><p>Given periodic shortages of <a class="drug drug_general" data-topicid="9551" href="/z/d/drug information/9551.html" rel="external">penicillin G benzathine</a>, it is important to follow recommended dosing regimens (eg, a single dose of penicillin G benzathine for early syphilis)  (<a class="graphic graphic_table graphicRef50435" href="/z/d/graphic/50435.html" rel="external">table 2</a>) [<a href="#rid6">6</a>]. In addition, use of penicillin G benzathine for syphilis treatment should be prioritized for pregnant women, and alternative regimens, such as <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>, may need to be utilized for nonpregnant adults if supplies are limited. (See <a class="local">'Alternative regimens for early syphilis'</a> below and  <a class="medical medical_review" href="/z/d/html/4794.html" rel="external">"Syphilis in pregnancy", section on 'Maternal treatment'</a>.)</p><p class="headingAnchor" id="H2109918330"><span class="h2">Patients who are allergic to penicillin</span><span class="headingEndMark"> — </span>If a patient is allergic to penicillin, the choice of agent is less clear. Options include:</p><p class="bulletIndent1"><span class="glyph">●</span>Testing for penicillin allergy and/or rechallenging with penicillin</p><p class="bulletIndent1"><span class="glyph">●</span>Desensitizing to penicillin if allergy testing is positive</p><p class="bulletIndent1"><span class="glyph">●</span>Using an alternative agent with close post-treatment monitoring</p><p></p><p class="headingAnchor" id="H120574454"><span class="h3">Who should be desensitized to penicillin</span><span class="headingEndMark"> — </span>Certain patients should be tested for penicillin allergy and desensitized to or rechallenged with penicillin rather than using an alternative agent. This includes those who are pregnant; those with ocular, otic, or neurosyphilis; those with cardiovascular manifestations of late syphilis; and/or those with treatment failure. Patients with a history of an immediate-type hypersensitivity reaction require desensitization. For patients with a history of a delayed-type reaction, some can be rechallenged with penicillin, while others should be evaluated by an allergist prior to being re-exposed. Detailed discussions of the management of patients with a penicillin allergy are found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2073.html" rel="external">"Penicillin allergy: Immediate reactions"</a> and  <a class="medical medical_review" href="/z/d/html/100191.html" rel="external">"Penicillin allergy: Delayed hypersensitivity reactions"</a>.)</p><p class="headingAnchor" id="H522749071"><span class="h3">Alternative agents</span><span class="headingEndMark"> — </span>For some patients (eg, nonpregnant person with early syphilis), it is reasonable to use an alternative agent rather than attempt desensitization or rechallenge with penicillin. Detailed information on regimen selection in specific patient populations is discussed below. (See <a class="local">'Treatment based on disease manifestation'</a> below.)</p><p>Alternative antimicrobial agents include tetracyclines (eg, <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>) and cephalosporins  (<a class="graphic graphic_table graphicRef50435" href="/z/d/graphic/50435.html" rel="external">table 2</a>), although some patients who are allergic to penicillin may also be allergic to cephalosporins. (See  <a class="medical medical_review" href="/z/d/html/2087.html" rel="external">"Allergy evaluation for immediate penicillin allergy: Skin test-based diagnostic strategies and cross-reactivity with other beta-lactam antibiotics"</a>.)</p><p>In general, we prefer <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> rather than other alternative agents. If a cephalosporin is used, most of the experience has been with <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> [<a href="#rid1">1</a>]; we prefer IV administration rather than IM injections, which are often painful. Oral <a class="drug drug_general" data-topicid="9216" href="/z/d/drug information/9216.html" rel="external">cefixime</a> has also been evaluated for treatment of early syphilis; however, data are limited. In an unblinded randomized trial of 58 patients with early syphilis in which patients received cefixime (400 mg orally twice daily) or <a class="drug drug_general" data-topicid="9551" href="/z/d/drug information/9551.html" rel="external">penicillin G benzathine</a> (2.4 million units IM), a ≥4-fold decrease in the rapid plasma reagin (RPR) titer was achieved in 56 and 81 percent of those who received cefixime or penicillin, respectively [<a href="#rid7">7</a>].</p><p>A single 2 g dose of <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> had previously been considered an alternative agent for early syphilis since it was found to be equivalent to <a class="drug drug_general" data-topicid="9551" href="/z/d/drug information/9551.html" rel="external">penicillin G benzathine</a> in clinical trials [<a href="#rid8">8-10</a>]. However, it is now recommended only if other agents are not available, given reports of treatment failures associated with macrolide resistance [<a href="#rid1">1,9,11-13</a>].</p><p>All patients who receive an alternative agent should be closely monitored after treatment. (See <a class="local">'Patient monitoring'</a> below.)</p><p class="headingAnchor" id="H3831003371"><span class="h1">TREATMENT BASED ON DISEASE MANIFESTATION</span><span class="headingEndMark"> — </span>For most patients, the treatment of syphilis depends upon the specific disease manifestation. Special considerations for the treatment of syphilis during pregnancy and in patients with HIV infection are presented separately. (See  <a class="medical medical_review" href="/z/d/html/4794.html" rel="external">"Syphilis in pregnancy"</a> and  <a class="medical medical_review" href="/z/d/html/7600.html" rel="external">"Syphilis in patients with HIV"</a>.)</p><p class="headingAnchor" id="H896098106"><span class="h2">Treatment of early syphilis</span><span class="headingEndMark"> — </span>The goals of treatment for early syphilis are to prevent long-term adverse outcomes of infection and reduce transmission to others. A diagnosis of early syphilis implies that <em>T. pallidum</em> infection occurred within the previous year.</p><p>Early syphilis refers to primary, secondary, and early latent syphilis.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary</strong> – Following acquisition of <em>T. pallidum</em>, the initial clinical manifestations are termed primary syphilis and usually consist of a painless chancre at the site of inoculation accompanied by regional adenopathy. (See  <a class="medical medical_review" href="/z/d/html/7584.html" rel="external">"Syphilis: Epidemiology, pathophysiology, and clinical manifestations in patients without HIV", section on 'Primary syphilis (chancre)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Secondary</strong> – Approximately 25 percent of individuals with untreated primary infection will develop a systemic illness that represents secondary syphilis. Clinical manifestations are protean, but often include a disseminated rash, condylomata lata, lymphadenopathy, alopecia, and/or hepatitis. (See  <a class="medical medical_review" href="/z/d/html/7584.html" rel="external">"Syphilis: Epidemiology, pathophysiology, and clinical manifestations in patients without HIV", section on 'Secondary syphilis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Early latent</strong> – Latent syphilis refers to the period when a patient is infected with <em>T. pallidum</em>, as demonstrated by serologic testing, but has no symptoms. Early latent syphilis by definition occurs within the first year of initial infection. Patients diagnosed with early latent syphilis should be considered to be potentially infectious. (See  <a class="medical medical_review" href="/z/d/html/7584.html" rel="external">"Syphilis: Epidemiology, pathophysiology, and clinical manifestations in patients without HIV", section on 'Latent syphilis (asymptomatic)'</a> and  <a class="medical medical_review" href="/z/d/html/7588.html" rel="external">"Syphilis: Screening and diagnostic testing", section on 'Latent syphilis'</a>.)</p><p></p><p class="bulletIndent1">If the timing of an infection is not known, a person is presumed to have late latent syphilis. The treatment of late latent syphilis is discussed below. (See <a class="local">'Late latent syphilis'</a> below.)</p><p></p><p class="headingAnchor" id="H658733542"><span class="h3">Preferred regimens for early syphilis</span><span class="headingEndMark"> — </span>Patients with neurologic, ocular, or otic manifestations of early syphilis require intravenous (IV) therapy. The management of these conditions are discussed below. (See <a class="local">'Treatment of neuro/ocular/otic syphilis'</a> below.)</p><p>For others, a single dose of <a class="drug drug_general" data-topicid="9551" href="/z/d/drug information/9551.html" rel="external">penicillin G benzathine</a> (2.4 million units intramuscularly [IM]) is standard therapy for primary, secondary, and early latent syphilis  (<a class="graphic graphic_table graphicRef50435" href="/z/d/graphic/50435.html" rel="external">table 2</a>) [<a href="#rid1">1,14</a>]. Long-acting penicillin G benzathine should only be given via the IM route [<a href="#rid4">4</a>]. Appropriate treatment for early syphilis requires persistent concentrations of penicillin to be sustained over a relatively long period of time, a requirement that is achieved in most patients with a single dose of penicillin G benzathine. A single 2.4 million unit dose of penicillin G benzathine maintains this serum concentration for about three weeks [<a href="#rid15">15</a>]. Increasing the dose does not clear treponemes more quickly [<a href="#rid16">16</a>]. </p><p>No resistance has been reported despite several decades of <a class="drug drug_general" data-topicid="9749" href="/z/d/drug information/9749.html" rel="external">penicillin G</a> use. However, sensitivity testing is not typically performed because the organism cannot be readily grown in the laboratory.</p><p>The use of single-dose treatment of early syphilis was supported in a systematic review, which included data from two large randomized clinical trials evaluating the efficacy of a single dose of 2.4 million units of IM <a class="drug drug_general" data-topicid="9551" href="/z/d/drug information/9551.html" rel="external">penicillin G benzathine</a> for the treatment of primary and secondary syphilis [<a href="#rid2">2,8,17</a>]. Clinical cure rates were 90 to 100 percent for both persons uninfected with HIV and persons infected with HIV. In addition, data from the 1950s suggested that long-acting depot penicillin therapy for early syphilis prevented subsequent development of late syphilis, including neurosyphilis [<a href="#rid18">18,19</a>]. Several studies have evaluated "enhanced" therapy with additional doses of penicillin G benzathine and found no additional benefit [<a href="#rid20">20-24</a>].</p><p class="headingAnchor" id="H560144467"><span class="h3">Alternative regimens for early syphilis</span><span class="headingEndMark"> — </span>Alternative regimens for early syphilis are generally avoided in patients with neurologic, ocular, or otic manifestations and during pregnancy. The management of these patients is discussed separately. (See <a class="local">'Treatment of neuro/ocular/otic syphilis'</a> below and  <a class="medical medical_review" href="/z/d/html/4794.html" rel="external">"Syphilis in pregnancy"</a>.)</p><p>For other patients, it is reasonable to use an alternative regimen in those with a penicillin allergy. Alternative regimens may also be needed when <a class="drug drug_general" data-topicid="9551" href="/z/d/drug information/9551.html" rel="external">penicillin G benzathine</a> is unavailable [<a href="#rid6">6</a>]. In general, we prefer <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> (100 mg orally twice daily for 14 days) as our first-line alternative agent in nonpregnant adults  (<a class="graphic graphic_table graphicRef50435" href="/z/d/graphic/50435.html" rel="external">table 2</a>). <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">Tetracycline</a> (500 mg orally four times daily for 14 days) can also be used, but adherence to this regimen may be challenging. Data from small, retrospective studies indicate serologic response rates of 83 to 100 percent when patients were treated with these agents [<a href="#rid25">25-31</a>]. <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">Minocycline</a> may also be used for treatment of early syphilis; however, in a retrospective study evaluating the use of minocycline, a 28-day course was administered, which is longer than the 14-day course used with doxycycline [<a href="#rid32">32</a>].</p><p><a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">Ceftriaxone</a> can also be used to treat early syphilis [<a href="#rid33">33-35</a>]; however, some patients who are allergic to penicillin may also be allergic to ceftriaxone. The regimen frequently studied and recommended by guidelines is 1 g (IM or IV) daily for 10 to 14 days [<a href="#rid1">1</a>]. Additional information on the use of cephalosporins is discussed above. (See <a class="local">'Patients who are allergic to penicillin'</a> above.)</p><p>For patients who are not allergic to penicillin, oral <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">amoxicillin</a> with <a class="drug drug_general" data-topicid="9812" href="/z/d/drug information/9812.html" rel="external">probenecid</a> is an option. Oral amoxicillin (3 g) <strong>plus</strong> probenecid (500 mg) are both given twice daily for 14 days. This regimen was evaluated in Japan (where <a class="drug drug_general" data-topicid="9551" href="/z/d/drug information/9551.html" rel="external">penicillin G benzathine</a> is not available) in a retrospective observational study of 286 persons with HIV who presented with all stages of syphilis [<a href="#rid36">36</a>]. The treatment duration was 14 to 30 days, and successful treatment was defined as at least a fourfold decline in nontreponemal titer. Approximately 95 percent of patients with early syphilis were successfully treated with this regimen.</p><p>Other agents, such as <a class="drug drug_general" data-topicid="9216" href="/z/d/drug information/9216.html" rel="external">cefixime</a> or <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a>, have some activity against <em>T. pallidum</em> but are generally not used for treatment of early syphilis. (See <a class="local">'Alternative agents'</a> above.)</p><p class="headingAnchor" id="H12"><span class="h2">Treatment of late syphilis</span><span class="headingEndMark"> — </span>Late syphilis includes late latent syphilis and tertiary syphilis. For most patients, <a class="drug drug_general" data-topicid="9551" href="/z/d/drug information/9551.html" rel="external">penicillin G benzathine</a> (2.4 million units IM once weekly for three weeks) provides adequate and persistent serum levels of penicillin  (<a class="graphic graphic_table graphicRef50435" href="/z/d/graphic/50435.html" rel="external">table 2</a>) [<a href="#rid1">1,14,18,19</a>]. However, patients with evidence of neurologic, otic, or ocular syphilis should be treated with IV therapy, as discussed below. (See <a class="local">'Treatment of neuro/ocular/otic syphilis'</a> below.)</p><p>There are limited data evaluating treatment regimens for late syphilis. Compared with early syphilis, longer duration of treatment should generally be administered since organisms might be dividing more slowly [<a href="#rid1">1</a>]. </p><p class="headingAnchor" id="H1744448962"><span class="h3">Late latent syphilis</span><span class="headingEndMark"> — </span>Latent syphilis refers to the period when a patient is infected with <em>T. pallidum</em>, as demonstrated by serologic testing, but has no symptoms. Late latent syphilis, by definition, is present for more than one year after initial infection. If the timing of an infection is not known, a person is presumed to have late latent syphilis (versus early latent syphilis, as discussed above) [<a href="#rid37">37</a>]. Transmission is unlikely to occur in this stage of disease; thus, the goal of therapy is to prevent complications of untreated syphilis. (See  <a class="medical medical_review" href="/z/d/html/7588.html" rel="external">"Syphilis: Screening and diagnostic testing", section on 'Latent syphilis'</a> and  <a class="medical medical_review" href="/z/d/html/7584.html" rel="external">"Syphilis: Epidemiology, pathophysiology, and clinical manifestations in patients without HIV", section on 'Latent syphilis (asymptomatic)'</a>.)</p><p>Patients with late latent syphilis should be treated with 2.4 million units of IM <a class="drug drug_general" data-topicid="9551" href="/z/d/drug information/9551.html" rel="external">penicillin G benzathine</a> once a week for three weeks (7.2 million units total)  (<a class="graphic graphic_table graphicRef50435" href="/z/d/graphic/50435.html" rel="external">table 2</a>) [<a href="#rid1">1</a>]. While this regimen has the advantage of not requiring daily patient adherence, it does require that the patient follow up consistently over the entire span of treatment to receive the full course of therapy. If a dose is delayed and more than 14 days have elapsed since the prior dose, the course should be reinitiated [<a href="#rid38">38</a>].</p><p>For nonpregnant patients with late latent syphilis who are penicillin allergic, <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> (100 mg orally twice daily) can be administered for 28 days [<a href="#rid1">1</a>]. <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">Tetracycline</a> or <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> are other alternatives  (<a class="graphic graphic_table graphicRef50435" href="/z/d/graphic/50435.html" rel="external">table 2</a>). However, there are very limited data on the efficacy of these alternative regimens for treatment of late syphilis; thus, we closely monitor the response to therapy [<a href="#rid39">39,40</a>]. (See <a class="local">'Patient monitoring'</a> below.)</p><p class="headingAnchor" id="H3487413634"><span class="h3">Tertiary syphilis</span><span class="headingEndMark"> — </span>Tertiary syphilis refers to patients with late syphilis who have symptomatic manifestations involving the cardiovascular system or gummatous diseases (usually of the skin and subcutaneous tissues). (See  <a class="medical medical_review" href="/z/d/html/7584.html" rel="external">"Syphilis: Epidemiology, pathophysiology, and clinical manifestations in patients without HIV", section on 'Late syphilis'</a>.)</p><p>Patients with gummatous or cardiovascular infection should have a cerebrospinal fluid (CSF) examination prior to initiation of therapy to assess for neurosyphilis. The management of neurosyphilis is described below. (See <a class="local">'Treatment of neuro/ocular/otic syphilis'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preferred antimicrobial regimen</strong> – If neurosyphilis is <strong>not</strong> present, we administer <a class="drug drug_general" data-topicid="9551" href="/z/d/drug information/9551.html" rel="external">penicillin G benzathine</a> (2.4 million units IM) once a week for three weeks [<a href="#rid1">1</a>]. Cutaneous gummas usually heal rapidly after penicillin therapy although with some scarring [<a href="#rid41">41-43</a>]. For those with cardiovascular disease, antibiotic therapy does not reverse the clinical manifestations of syphilis, but it may halt progression of disease. Similar to the treatment of late latent syphilis, if a patient misses a dose, and if more than 14 days have elapsed since the prior dose, the course should be reinitiated [<a href="#rid38">38</a>]. This approach is consistent with guideline recommendations from the United States Centers for Disease Control and Prevention (CDC) [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alternative antimicrobial regimens</strong> – For penicillin-allergic patients with tertiary syphilis, we desensitize or rechallenge with penicillin, if possible. More detailed discussions of how to evaluate patients for penicillin allergy are presented elsewhere. (See <a class="local">'Who should be desensitized to penicillin'</a> above and  <a class="medical medical_review" href="/z/d/html/2087.html" rel="external">"Allergy evaluation for immediate penicillin allergy: Skin test-based diagnostic strategies and cross-reactivity with other beta-lactam antibiotics"</a>.)</p><p></p><p class="bulletIndent1">If desensitization is not possible, treatment options include <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> (100 mg orally twice daily for 28 days) or <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> (2 g IV or IM daily for 10 to 14 days) if the patient can be safely treated with other beta-lactam drugs. There are no data to support one approach over the other; however, we generally prefer ceftriaxone to ensure the full duration of treatment is completed.</p><p></p><p class="headingAnchor" id="H15"><span class="h2">Treatment of neuro/ocular/otic syphilis</span><span class="headingEndMark"> — </span>Neurosyphilis, ocular syphilis, and otic syphilis can occur at any time during the course of infection  (<a class="graphic graphic_table graphicRef50435" href="/z/d/graphic/50435.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/7599.html" rel="external">"Neurosyphilis", section on 'Clinical manifestations'</a> and  <a class="medical medical_review" href="/z/d/html/7584.html" rel="external">"Syphilis: Epidemiology, pathophysiology, and clinical manifestations in patients without HIV", section on 'Clinical manifestations'</a>.)</p><p></p><p>The treatment of ocular and otic syphilis is the same as that for neurosyphilis, even if there is no evidence of central nervous system involvement on CSF testing. Indications for CSF testing are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7588.html" rel="external">"Syphilis: Screening and diagnostic testing", section on 'Patients with ocular/otic symptoms'</a>.)</p><p>Long-acting IM <a class="drug drug_general" data-topicid="9551" href="/z/d/drug information/9551.html" rel="external">penicillin G benzathine</a> does not penetrate "protected sites" that sequester <em>T. pallidum </em>(eg, ocular structures, the central nervous system). (See <a class="local">'Penicillin as the treatment of choice'</a> above.)</p><p class="headingAnchor" id="H16"><span class="h3">Preferred regimens</span><span class="headingEndMark"> — </span>Patients with ocular, otic, or neurosyphilis should be treated with IV <a class="drug drug_general" data-topicid="9749" href="/z/d/drug information/9749.html" rel="external">penicillin G</a> (3 to 4 million units IV every four hours or 18 to 24 million units per day by continuous infusion) for 10 to 14 days  (<a class="graphic graphic_table graphicRef50435" href="/z/d/graphic/50435.html" rel="external">table 2</a>) [<a href="#rid1">1</a>]. The dose of IM <a class="drug drug_general" data-topicid="9551" href="/z/d/drug information/9551.html" rel="external">penicillin G benzathine</a> that is used for treatment of other stages of syphilis does not produce measurable CSF levels of the drug [<a href="#rid44">44</a>]. In addition, there are several case reports of patients with HIV who were treated with penicillin G benzathine and subsequently developed symptomatic neurosyphilis; in some of these cases, viable <em>T. pallidum</em> were demonstrated in CSF after IM therapy [<a href="#rid18">18,19,45,46</a>].</p><p>For patients with late disease (ie, infection felt to be present for more than a year, such as general paresis or tabes dorsalis), we typically suggest a single dose of <a class="drug drug_general" data-topicid="9551" href="/z/d/drug information/9551.html" rel="external">penicillin G benzathine</a> (2.4 million units IM) be administered after the course of IV penicillin is completed since the duration of treatment for neurosyphilis is shorter than the regimens used for other forms of late syphilis. This approach is based upon the pathophysiology of the organism, the required drug levels needed to eradicate the organism in later stages of disease, and the overall safety of the drug. However, some patients and providers may prefer to defer this additional dose since the benefit is theoretical, and there are no data to support any firm recommendations [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H658733727"><span class="h3">Alternative regimens</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with penicillin allergy</strong> – Patients with neurosyphilis and a penicillin allergy should be evaluated to see if they can be desensitized to or rechallenged with penicillin. This way they can receive the standard IV regimen rather than using an alternative regimen  (<a class="graphic graphic_table graphicRef50435" href="/z/d/graphic/50435.html" rel="external">table 2</a>). The approach to patients with a penicillin allergy is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2073.html" rel="external">"Penicillin allergy: Immediate reactions"</a> and  <a class="medical medical_review" href="/z/d/html/100191.html" rel="external">"Penicillin allergy: Delayed hypersensitivity reactions"</a> and <a class="local">'Preferred regimens'</a> above.)</p><p></p><p class="bulletIndent1">If desensitization or rechallenge with penicillin is not feasible, <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> (2 g IV daily for 10 to 14 days) is a reasonable alternative for those who are able to tolerate cephalosporins. The United States CDC states the dose of ceftriaxone for treatment of neurosyphilis is 1 to 2 g [<a href="#rid1">1</a>]; however, we prefer the 2 g dose since most of the studies evaluating ceftriaxone have used the 2 g dose.</p><p></p><p class="bulletIndent1">Although there is much less experience with <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> compared with penicillin, observational data support the use of ceftriaxone for treatment of ocular, otic, or early neurosyphilis [<a href="#rid47">47,48</a>]. In one report of 365 patients with neurosyphilis (42 in the ceftriaxone group and 166 in the penicillin group), patients who received ceftriaxone were more likely to have a clinical response to treatment (98 versus 76 percent, respectively; crude odds ratio 13.02, 95% CI 1.73-97.66) [<a href="#rid47">47</a>]. In this trial, a similar number of patients in each group achieved an appropriate serological response at six months (88 versus 82 percent for ceftriaxone and penicillin, respectively).</p><p></p><p class="bulletIndent1">On rare occasions a patient may not be able to be desensitized to penicillin or take a cephalosporin (eg, patients with Stevens-Johnson syndrome). In this setting, <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> (200 mg orally twice daily) for 21 to 28 days can be used. However, this regimen should be reserved for these exceptional circumstances since this regimen has very limited supporting data [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alternative to IV therapy</strong> – There are no well-established alternatives to IV therapy for treatment of neurosyphilis. Previously, <a class="drug drug_general" data-topicid="9750" href="/z/d/drug information/9750.html" rel="external">penicillin G procaine</a> (2.4 million units IM once daily) <strong>plus</strong> <a class="drug drug_general" data-topicid="9812" href="/z/d/drug information/9812.html" rel="external">probenecid</a> (500 mg orally four times a day) was an option [<a href="#rid50">50</a>], but penicillin G procaine has been discontinued worldwide. </p><p></p><p class="headingAnchor" id="H1470548725"><span class="h3">When the diagnosis of neurosyphilis is unclear</span><span class="headingEndMark"> — </span>In certain settings the diagnosis of neurosyphilis cannot be confirmed. When this occurs, the approach to treatment must be individualized and depends upon the clinical suspicion for neurosyphilis.</p><p>As an example, we would treat a patient for neurosyphilis with IV <a class="drug drug_general" data-topicid="9749" href="/z/d/drug information/9749.html" rel="external">penicillin G</a> if they had a compatible clinical syndrome, risk factors for syphilis, reactive blood serology for syphilis, and a CSF pleocytosis, even if the CSF-Venereal Disease Research Laboratory (VDRL) was not reactive. The CSF-VDRL test may be falsely negative in as many as 70 percent of patients with neurosyphilis. (See  <a class="medical medical_review" href="/z/d/html/7599.html" rel="external">"Neurosyphilis", section on 'Diagnosis'</a>.)</p><p>By contrast, if there is a low suspicion for neurosyphilis, we may treat for late latent syphilis (ie, three weekly doses of <a class="drug drug_general" data-topicid="9551" href="/z/d/drug information/9551.html" rel="external">penicillin G benzathine</a> 2.4 million units IM), rather than administer IV treatment. This situation typically occurs in older patients with mild cognitive deficits consistent with early dementia for whom the risk and inconvenience of sampling CSF and/or administering IV therapy may exceed the risk of undertreated neurosyphilis. If symptoms are more specific for neurosyphilis, IV penicillin can be given even when CSF sampling cannot be done.</p><p class="headingAnchor" id="H1734264770"><span class="h1">MANAGEMENT OF PREGNANT PERSONS</span><span class="headingEndMark"> — </span>Pregnant persons with syphilis should be treated with penicillin. The formulation and dose depend upon the disease manifestation. Those who are allergic to penicillin should be managed in conjunction with an allergist so they can be desensitized or rechallenged and treated with <a class="drug drug_general" data-topicid="9749" href="/z/d/drug information/9749.html" rel="external">penicillin G</a>. Syphilis in pregnancy is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4794.html" rel="external">"Syphilis in pregnancy"</a>.)</p><p class="headingAnchor" id="H658733904"><span class="h1">PATIENT MONITORING</span><span class="headingEndMark"> — </span>Patients should be monitored clinically and with laboratory testing to ensure they are responding appropriately to therapy.</p><p class="headingAnchor" id="H1809593866"><span class="h2">Jarisch-Herxheimer reaction</span><span class="headingEndMark"> — </span>The Jarisch-Herxheimer reaction (JHR) is an acute, self-limited, febrile reaction that usually occurs within the first 24 hours after the patient receives therapy for any spirochetal infection, including syphilis. This reaction occurs in approximately 10 to 35 percent of cases [<a href="#rid24">24,51</a>]. It is seen most commonly after treatment of early syphilis.</p><p>The fever may be accompanied by systemic symptoms including headache, myalgias, rigors, diaphoresis, hypotension, and worsening of rash if initially present. Uncommon manifestations include meningitis, respiratory distress, renal and/or hepatic dysfunction, mental status changes, stroke, seizures, and uterine contractions in pregnancy [<a href="#rid52">52</a>]. An additional discussion of the JHR in pregnancy is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4794.html" rel="external">"Syphilis in pregnancy", section on 'Potential complications of treatment: Jarisch-Herxheimer reaction'</a>.)</p><p>The mechanism by which this reaction develops is not completely understood. However, it is thought to result from accelerated phagocytosis by polymorphonuclear leukocytes, followed by the release of lipoproteins, cytokines, and immune complexes from killed organisms [<a href="#rid51">51,53,54</a>].</p><p>There is no way to prevent this reaction. Patients should be informed of the possible signs and symptoms and advised to contact their clinicians if a severe reaction occurs. Although these symptoms often resolve without intervention within 12 to 24 hours, nonsteroidal anti-inflammatory drugs (NSAIDS) or other antipyretics can be used if symptoms arise, and they may reduce the severity of symptoms and the duration of the reaction.</p><p class="headingAnchor" id="H1029295266"><span class="h2">Clinical assessment</span><span class="headingEndMark"> — </span>Patients with early syphilis should be assessed clinically for resolution of symptoms (eg, rash, ulcer). However, for patients with late stage cardiovascular or noncutaneous gummatous disease, a significant change in symptoms is unlikely.</p><p class="headingAnchor" id="H1002816367"><span class="h2">Serologic testing</span><span class="headingEndMark"> — </span>Nontreponemal (rapid plasma reagin [RPR] or Venereal Disease Research Laboratory [VDRL]) titers should be monitored after treatment. Since <em>T. pallidum</em> cannot be cultured in the laboratory, the success of treatment must be inferred through this indirect measure. Although definitive criteria for cure or failure have not been established, the United States Centers for Disease Control and Prevention (CDC) has suggested definitions to assess the patient's response to treatment [<a href="#rid1">1</a>]. A description of the types of serologic tests used to diagnose and monitor syphilis is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7588.html" rel="external">"Syphilis: Screening and diagnostic testing", section on 'Serologic tests'</a>.)</p><p class="headingAnchor" id="H1511323406"><span class="h3">Assessing response</span><span class="headingEndMark"> — </span>A fourfold decline in the nontreponemal titer, equivalent to a change of two dilutions (eg, from 1:32 to 1:8 or from 1:16 to 1:4), is considered an adequate serologic response. Over time, most patients successfully treated for syphilis experience seroreversion; however, some do not.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Seroreversion</strong> – The loss of nontreponemal antibodies over time (seroreversion) in a patient who has been successfully treated for syphilis is considered to be consistent with clinical cure. The majority of patients who are treated for early syphilis will experience seroreversion over time. Once the nontreponemal titer has become nonreactive, additional testing is not needed unless it is being done because of concerns for a new infection. (See <a class="local">'Patient monitoring'</a> above.)</p><p></p><p class="bulletIndent1">Although seroreversion is typically seen with nontreponemal antibodies, seroreversion of treponemal tests has also been reported, with rates as high as 24 percent (particularly in patients treated early during primary syphilis) [<a href="#rid55">55,56</a>].</p><p></p><p class="bulletIndent1">In the rare instance in which treatment is initiated prior to any detectable serologic response (eg, primary syphilis diagnosed clinically or by direct spirochete detection), serologic testing may remain nonreactive.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fourfold or greater decline in titer</strong> – A fourfold decline in the nontreponemal titer, equivalent to a change of two dilutions (eg, from 1:16 to 1:4 or from 1:32 to 1:8), is considered an adequate response to syphilis therapy. The duration of time it takes to achieve this is depends on the stage of disease, as discussed above. (See <a class="local">'How often to monitor'</a> below.)</p><p></p><p class="bulletIndent1">In a systematic review that included data from 20 studies, a fourfold or greater decline in nontreponemal titers was associated with younger age, higher baseline nontreponemal titers, and earlier syphilis stage [<a href="#rid57">57</a>].</p><p></p><p class="bulletIndent1">Some patients may have nontreponemal titers that decline ≥4-fold but do not serorevert or continue to fall after 12 to 24 months of monitoring; this had previously been referred to as being serofast. As long as the titers do not start to increase, retreatment is usually not needed. The frequency with which we repeat testing depends on the ongoing risk for infection. As an example, if the person is at risk for reinfection, we would check titers every three months at first, and then at increasing intervals (eg, every six months and then annually) to assess for possible late failure or reinfection.</p><p></p><p class="bulletIndent1">In one study, fewer than half of patients who were treated for syphilis became seronegative within five years [<a href="#rid58">58</a>]. Nontreponemal titers often stabilize at a low level (eg, a titer of &lt;1:8) after an initial fourfold or greater decline. However, higher titers are occasionally seen, particularly in persons with HIV due to immunodysregulation of antibody production [<a href="#rid1">1</a>]. Individuals with persistently high titers should be tested for HIV infection if testing has not been recently performed. (See  <a class="medical medical_review" href="/z/d/html/3736.html" rel="external">"Screening and diagnostic testing for HIV infection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Less than fourfold decline in titer</strong> – Most patients who have less than a fourfold decline in titers are considered to have treatment failure or reinfection, as discussed below. However, some patients (eg, those with antibody titers &lt;1:8) may be less likely to have a fourfold decline than those with higher titers. The evaluation of patients with possible treatment failure is discussed below. (See <a class="local">'Persons with an inadequate response to treatment'</a> below.)</p><p></p><p class="headingAnchor" id="H1915820577"><span class="h3">How often to monitor</span><span class="headingEndMark"> — </span>Whenever possible, a nontreponemal titer should be obtained just before initiating therapy (ideally, on the first day of treatment) since titers can change significantly in the time between diagnosis of syphilis and treatment initiation. In a study of 766 persons treated for syphilis in Australia, in which the median time between diagnosis and treatment was six days, 113 patients (14.8 percent) had a &gt;4-fold change in RPR titer during the interval between diagnosis and treatment [<a href="#rid59">59</a>]. </p><p>Follow-up testing depends upon the stage of infection:</p><p class="bulletIndent1"><span class="glyph">●</span>In patients with early syphilis, serologic testing should be performed 6 and 12 months following treatment and at any time if clinical symptoms recur. In general, such patients should experience an adequate response by 12 months. (See <a class="local">'Assessing response'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with late syphilis (including late latent syphilis) should undergo follow-up serologic testing at 6, 12, and 24 months, as some patients with late syphilis may not have an adequate response for up to two years following treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with HIV are typically monitored more frequently. The management of patients infected with HIV with syphilis is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7600.html" rel="external">"Syphilis in patients with HIV"</a>.)</p><p></p><p>Antibody titers decline at varying rates following treatment, depending upon the stage of infection and the magnitude of the pretreatment titer. Patients with early syphilis may experience more rapid relative declines in RPR titers than patients with late syphilis. As an example, in a systematic review, serologic response to treatment was typically seen by six months in patients with early syphilis, but generally demonstrated a slower decline (12 to 24 months) in patients with late latent disease [<a href="#rid2">2</a>]. Other factors that may slow the rate at which titers decline following therapy include prior episodes of syphilis, the duration of infection prior to therapy, and the presence of HIV coinfection [<a href="#rid39">39,55,60</a>].</p><p class="headingAnchor" id="H3727703051"><span class="h2">Patients with neurosyphilis</span><span class="headingEndMark"> — </span>Patients with neurosyphilis should undergo clinical and serologic monitoring at the same frequency as patients without neurosyphilis. In addition, monitoring of cerebrospinal fluid (CSF) abnormalities may also be warranted. A discussion of monitoring after treatment for neurosyphilis is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7599.html" rel="external">"Neurosyphilis"</a>.)</p><p class="headingAnchor" id="H658734623"><span class="h1">PERSONS WITH AN INADEQUATE RESPONSE TO TREATMENT</span><span class="headingEndMark"> — </span>If a patient has not had an adequate response to treatment (eg, persistent signs or symptoms, a documented fourfold increase in nontreponemal titers for &gt;2 weeks after an initial decline, &lt;4-fold decrease in nontreponemal titer), it is important to determine if the individual has been reinfected, is experiencing a slow response to treatment, or has failed treatment. Since drug resistance to penicillin has not been described, treatment failure is likely due to poor adherence with the treatment regimen, treatment with an alternative agent, immunocompromised status, or undiagnosed central nervous system disease.</p><p class="headingAnchor" id="H4197792026"><span class="h2">Patients without HIV</span></p><p class="headingAnchor" id="H994222862"><span class="h3">Evaluation and management</span><span class="headingEndMark"> — </span>Our approach to patients without HIV who have had an inadequate response to therapy is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>We first assess the patient to see if there is a history of possible new exposure or clinical evidence of a new infection (eg, chancre, rash). In addition, we repeat testing for HIV.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If there is no evidence of new infection, we then assess for evidence of potential neurosyphilis. We perform a lumbar puncture (LP) in those who present with any of the following signs or symptoms:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Neurologic symptoms (eg, cranial nerve dysfunction).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Signs or symptoms of syphilis that persist or recur.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>A fourfold or greater increase in nontreponemal test titers persisting for &gt;2 weeks in patients with no sexual exposure during the previous year.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Persons treated for late latent syphilis with an initially high titer (≥1:32) that fails to decline at least four-fold within 24 months of treatment. If the cerebrospinal fluid (CSF) is abnormal, then the patient needs a treatment course for neurosyphilis. (See <a class="local">'Treatment of neuro/ocular/otic syphilis'</a> above.)</p><p></p><p class="bulletIndent3">If the CSF is unremarkable, but there continues to be concern for treatment failure, we retreat the patient with another course of therapy. This should be accomplished with a regimen recommended for late syphilis, even if the initial presentation was early syphilis. Such patients who failed an alternative regimen should be reassessed to see if penicillin can be administered. In the case of reported penicillin allergy, testing for true allergy should be pursued, and if present, the patient should undergo desensitization.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If there is no evidence of new infection and an LP is not indicated, patients can be treated with weekly injections of <a class="drug drug_general" data-topicid="9551" href="/z/d/drug information/9551.html" rel="external">benzathine penicillin</a> G 2.4 million units intramuscularly (IM) for three weeks. However, for some patients (eg, those with a baseline titer &lt;1:8), clinical assessment and serologic testing every six months is a reasonable option for those who are considered likely to be adherent with follow up visits. If the titer remains stable, the time interval between assessments can be increased over time.</p><p></p><p class="bulletIndent1">If the patient has been retreated, we continue close clinical and serologic follow-up (eg, every six months) and determine the need for additional evaluation and management based upon subsequent changes in nontreponemal titers.</p><p></p><p class="headingAnchor" id="H2915504992"><span class="h3">Additional considerations</span><span class="headingEndMark"> — </span>When an alternative regimen has been used because of a reported penicillin allergy and treatment response is inadequate (ie, nontreponemal titers fail to decline fourfold within 12 months of treatment), it is reasonable to test for penicillin allergy and consider treatment with <a class="drug drug_general" data-topicid="9551" href="/z/d/drug information/9551.html" rel="external">penicillin G benzathine</a> in those whose allergy testing is negative. If treatment with penicillin is not possible, the management plan should be formulated on a case-by-case basis; the primary options are to continue monitoring nontreponemal titers closely (and retreat if the titer increases) or to perform an LP to evaluate for neurosyphilis. An additional discussion of the treatment of patients who are allergic to penicillin is found above. (See <a class="local">'Patients who are allergic to penicillin'</a> above.)</p><p>For patients with neurosyphilis and evidence of treatment failure, retreatment usually requires 14 days of intravenous (IV) <a class="drug drug_general" data-topicid="9749" href="/z/d/drug information/9749.html" rel="external">penicillin G</a>. There is no evidence that longer courses of treatment or use of different antibiotics change the outcome.</p><p class="headingAnchor" id="H42809156"><span class="h2">Patients with HIV</span><span class="headingEndMark"> — </span>The approach to patients with HIV and possible treatment failure is similar to those without HIV. However, if there is no evidence for new infection, an LP is indicated for most patients. This is discussed in greater detail in a separate topic review. (See  <a class="medical medical_review" href="/z/d/html/7600.html" rel="external">"Syphilis in patients with HIV"</a>.)</p><p class="headingAnchor" id="H27"><span class="h1">TREATMENT AFTER AN EXPOSURE</span><span class="headingEndMark"> — </span>There is no vaccine for syphilis. Thus, persons exposed sexually to a partner who has syphilis in any stage should be evaluated clinically and serologically for evidence of infection.</p><p class="bulletIndent1"><span class="glyph">●</span>If the patient has clinical evidence of syphilis, treatment is tailored to the specific manifestation as summarized in the table  (<a class="graphic graphic_table graphicRef50435" href="/z/d/graphic/50435.html" rel="external">table 2</a>) and described in more detail above. (See <a class="local">'Treatment of early syphilis'</a> above and <a class="local">'Treatment of neuro/ocular/otic syphilis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For those who are asymptomatic, we treat empirically for early syphilis if the patient had condomless oral, anal, or vaginal sex with:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A sex partner who was diagnosed with primary, secondary, or early latent syphilis within the preceding 90 days.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A sex partner who was diagnosed with late latent syphilis within the preceding 90 days if the partner had a high nontreponemal titer (eg, &gt;1:32). A high serologic titer is often associated with early infection, and the patient may have been misdiagnosed with late disease when in fact infection occurred more recently.</p><p></p><p class="bulletIndent1">For such patients, baseline serologic testing is performed at the time of presentation, although we do not withhold treatment pending serology results. Serologic testing may be negative in those with incubating or early disease. However, if nontreponemal testing is positive, it should be used to monitor the response to therapy. (See <a class="local">'Serologic testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For asymptomatic patients who were exposed to a sex partner with syphilis more than 90 days preceding their partner's diagnosis, we generally determine the need for treatment based upon the results of baseline serologic testing. However, if serologic testing is not readily available, or if follow up is uncertain, we treat empirically. The specific treatment regimen depends upon when the patient was exposed (ie, early versus late latent syphilis). In general, we prefer to treat persons in this setting whose exposure is uncertain since the risk of undertreatment typically exceeds that of overtreatment. (See <a class="local">'Treatment of early syphilis'</a> above and <a class="local">'Treatment of late syphilis'</a> above.)</p><p></p><p class="headingAnchor" id="H2939628349"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/111582.html" rel="external">"Society guideline links: Sexually transmitted infections"</a>.)</p><p class="headingAnchor" id="H24216235"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/17045.html" rel="external">"Patient education: Syphilis (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H28"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Natural history</strong> – Syphilis is caused by the bacterium <em>Treponema pallidum</em>. If untreated, syphilis can have a number of significant late manifestations including cardiovascular, gummatous, and neurologic complications. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretreatment considerations</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Stage and classification of disease</strong> – Recommended treatments are specific to stage and location of disease. These are defined in the table  (<a class="graphic graphic_table graphicRef50435" href="/z/d/graphic/50435.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Serology</strong> – A nontreponemal titer (eg, rapid plasma reagin [RPR], Venereal Disease Research Laboratory [VDRL]) should be obtained just before initiating therapy (ideally, on the first day of treatment). Titers can increase between diagnosis and treatment initiation, even in a few days. (See <a class="local">'Pretreatment evaluation'</a> above.)</p><p></p><p class="bulletIndent2">Nontreponemal titers are used to monitor response to treatment. Although treponemal titers are more specific, they are not used for monitoring since they are reported as qualitative rather than quantitative and may remain positive for life. (See  <a class="medical medical_review" href="/z/d/html/7588.html" rel="external">"Syphilis: Screening and diagnostic testing"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of</strong> <strong>early syphilis</strong> – For adults with early syphilis (primary, secondary, and early latent syphilis) without neurosyphilis, we suggest a single dose of <a class="drug drug_general" data-topicid="9551" href="/z/d/drug information/9551.html" rel="external">penicillin G benzathine</a> (2.4 million units intramuscularly [IM]) rather than an extended course of penicillin therapy (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). Clinical cure rates are high (&gt;90 percent) with this single-dose regimen. </p><p></p><p class="bulletIndent1">Alternative regimens for nonpregnant patients are summarized in the table  (<a class="graphic graphic_table graphicRef50435" href="/z/d/graphic/50435.html" rel="external">table 2</a>). (See <a class="local">'Treatment of early syphilis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Late syphilis</strong> – For patients with late latent syphilis or tertiary syphilis (gummatous or cardiovascular disease) without evidence of neurosyphilis, we suggest IM <a class="drug drug_general" data-topicid="9551" href="/z/d/drug information/9551.html" rel="external">penicillin G benzathine</a> 2.4 million units once weekly for three weeks (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). This longer duration of treatment is advised for late syphilis since organisms might be dividing more slowly. </p><p></p><p class="bulletIndent1">If a patient misses a dose, and if more than 14 days have elapsed since the prior dose, the three dose series should be reinitiated. (See <a class="local">'Treatment of late syphilis'</a> above.)</p><p></p><p class="bulletIndent1">Alternative regimens for nonpregnant patients are summarized in the table  (<a class="graphic graphic_table graphicRef50435" href="/z/d/graphic/50435.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of</strong> <strong>neurologic, ocular, or otic syphilis</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Neurosyphilis</strong> – For patients with neurosyphilis, we recommend treatment with IV <a class="drug drug_general" data-topicid="9749" href="/z/d/drug information/9749.html" rel="external">penicillin G</a> (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). IV therapy is required to achieve adequate levels in the cerebrospinal fluid (CSF). (See <a class="local">'Preferred regimens'</a> above.)</p><p></p><p class="bulletIndent2">For patients with clinical manifestations of late disease (eg, general paresis or tabes dorsalis), we suggest an additional single dose of IM <a class="drug drug_general" data-topicid="9551" href="/z/d/drug information/9551.html" rel="external">penicillin G benzathine</a> after the IV course (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Without this IM dose, the duration of treatment for neurosyphilis is shorter than the regimens used for other forms of late syphilis and may be insufficient. However, data supporting this approach are lacking, and it is reasonable for a patient or provider to defer this additional dose.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ocular or otic syphilis</strong> – We also suggest IV penicillin for those with ocular or otic disease, even if CSF testing is normal (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). IM <a class="drug drug_general" data-topicid="9551" href="/z/d/drug information/9551.html" rel="external">penicillin G benzathine</a> may not penetrate these "protected sites" that sequester <em>T. pallidum.</em> (See <a class="local">'Preferred regimens'</a> above.)</p><p></p><p class="bulletIndent1">Specific treatment regimens are summarized in the table  (<a class="graphic graphic_table graphicRef50435" href="/z/d/graphic/50435.html" rel="external">table 2</a>). (See <a class="local">'Treatment of neuro/ocular/otic syphilis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of patients allergic to penicillin</strong> – For selected patients with a reported penicillin allergy, we suggest allergy testing followed by desensitization or rechallenge with penicillin (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). This includes pregnant patients; those with ocular, otic, or neurosyphilis; those with cardiovascular manifestations of late syphilis; and/or those with treatment failure. (See <a class="local">'Patients who are allergic to penicillin'</a> above.)</p><p></p><p class="bulletIndent1">For others, alternative treatment options may include <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> and <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a>  (<a class="graphic graphic_table graphicRef50435" href="/z/d/graphic/50435.html" rel="external">table 2</a>). . (See <a class="local">'Alternative regimens for early syphilis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assessing treatment response</strong> – For patients without HIV the frequency of serologic testing depends upon the stage of disease (see <a class="local">'Serologic testing'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Early syphilis – Six and 12 months following treatment; an adequate response is expected by 12 months.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Late syphilis – Six, 12, and 24 months following treatment; it may take up to two years to achieve an adequate response in patients with late syphilis.</p><p></p><p class="bulletIndent1">Patients with HIV are typically monitored more frequently. (See  <a class="medical medical_review" href="/z/d/html/7600.html" rel="external">"Syphilis in patients with HIV"</a>.)</p><p></p><p class="bulletIndent1">Patients with neurosyphilis and persistent symptoms may also warrant CSF monitoring. (See <a class="local">'Patients with neurosyphilis'</a> above.)</p><p></p><p class="bulletIndent1">A fourfold decline in the <strong>nontreponemal</strong> titer, equivalent to a change of two dilutions (eg, from 1:32 to 1:8 or from 1:16 to 1:4), is considered an adequate serologic response. Over time, most but not all patients successfully treated for syphilis serorevert (nonreactive nontreponemal test). In contrast, <strong>treponemal</strong> titers may remain positive for life even after successful treatment. (See <a class="local">'Clinical assessment'</a> above and <a class="local">'Serologic testing'</a> above.)</p><p></p><p class="bulletIndent1">If a patient has not had an adequate response to therapy, this may indicate treatment failure, reinfection, or a slow response. Such patients require further evaluation, and possibly additional treatment. Treatment failure is likely due to poor adherence with the treatment regimen, treatment with an alternative agent, immunocompromised status, or undiagnosed central nervous system disease. (See <a class="local">'Persons with an inadequate response to treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of other STIs and sexual partners</strong> – We evaluate all patients with syphilis for other sexually transmitted infections (STIs)  (<a class="graphic graphic_table graphicRef103391" href="/z/d/graphic/103391.html" rel="external">table 1</a>). </p><p></p><p class="bulletIndent1">Sexual partners should be evaluated clinically and serologically for evidence of infection. The need for empiric treatment depends upon when the exposure occurred and the stage of their partner's infection. (See <a class="local">'Treatment after an exposure'</a> above.)</p><p></p><p><strong>ACKNOWLEDGMENT</strong> — The UpToDate editorial staff acknowledges P Frederick Sparling, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021; 70:1.</a></li><li><a class="nounderline abstract_t">Clement ME, Okeke NL, Hicks CB. Treatment of syphilis: a systematic review. JAMA 2014; 312:1905.</a></li><li><a class="nounderline abstract_t">MAGNUSON HJ, THOMAS EW, OLANSKY S, et al. Inoculation syphilis in human volunteers. Medicine (Baltimore) 1956; 35:33.</a></li><li class="breakAll">The pink sheet. F-D-C Reports. Chevy Chase, MD 2004, p.17.</li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Inadvertent use of Bicillin C-R to treat syphilis infection--Los Angeles, California, 1999-2004. MMWR Morb Mortal Wkly Rep 2005; 54:217.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Bicillin-LA (benzathine penicillin G) shortage. http://www.cdc.gov/std/treatment/drugnotices/bicillinshortage.htm (Accessed on May 26, 2016).</li><li><a class="nounderline abstract_t">Stafylis C, Keith K, Mehta S, et al. Clinical Efficacy of Cefixime for the Treatment of Early Syphilis. Clin Infect Dis 2021; 73:907.</a></li><li><a class="nounderline abstract_t">Riedner G, Rusizoka M, Todd J, et al. Single-dose azithromycin versus penicillin G benzathine for the treatment of early syphilis. N Engl J Med 2005; 353:1236.</a></li><li><a class="nounderline abstract_t">Hook EW 3rd, Behets F, Van Damme K, et al. A phase III equivalence trial of azithromycin versus benzathine penicillin for treatment of early syphilis. J Infect Dis 2010; 201:1729.</a></li><li class="breakAll">Bai ZG, Wang B, Yang K, Tian JH, Ma B, Liu Y, Jiang L, Gai QY, He X, LiY. Azithromycin versus penicillin G benzathine for early syphilis. Cochrane Database of Systematic Reviews 2012, Issue 6. Art No.: CD007270.</li><li><a class="nounderline abstract_t">Martin IE, Gu W, Yang Y, Tsang RS. Macrolide resistance and molecular types of Treponema pallidum causing primary syphilis in Shanghai, China. Clin Infect Dis 2009; 49:515.</a></li><li><a class="nounderline abstract_t">Van Damme K, Behets F, Ravelomanana N, et al. Evaluation of azithromycin resistance in Treponema pallidum specimens from Madagascar. Sex Transm Dis 2009; 36:775.</a></li><li><a class="nounderline abstract_t">Marra CM, Colina AP, Godornes C, et al. Antibiotic selection may contribute to increases in macrolide-resistant Treponema pallidum. J Infect Dis 2006; 194:1771.</a></li><li class="breakAll">World Health Organization. Guidelines for the treatment of Treponema Pallidum. http://apps.who.int/iris/bitstream/10665/249572/1/9789241549806-eng.pdf?ua=1 (Accessed on September 07, 2016).</li><li><a class="nounderline abstract_t">Rein MF. Biopharmacology of syphilotherapy. J Am Vener Dis Assoc 1976; 3:109.</a></li><li><a class="nounderline abstract_t">Tramont EC. Persistence of Treponema pallidum following penicillin G therapy. Report of two cases. JAMA 1976; 236:2206.</a></li><li><a class="nounderline abstract_t">Rolfs RT, Joesoef MR, Hendershot EF, et al. A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection. The Syphilis and HIV Study Group. N Engl J Med 1997; 337:307.</a></li><li class="breakAll">Swartz MN, Healy BP, Musher DM. Late syphilis. In: Sexually Transmitted Diseases, Holmes KK, Sparling PF, Mardh PA, et al (Eds), McGraw Hill, New York City 1999. p.487.</li><li><a class="nounderline abstract_t">Scheck DN, Hook EW 3rd. Neurosyphilis. Infect Dis Clin North Am 1994; 8:769.</a></li><li class="breakAll">Taiwan HIV and Syphilis Study Group. Comparison of effectiveness of 1 dose versus 3 doses of benzathine penicillin in the treatment of early syphilis in HIV-infected patients: Prospective observational study in Taiwan [abstract S-119]. In: Conference on Retroviruses and Opportu- nistic Infections, Atlanta, GA, 3–6 March 2013.</li><li><a class="nounderline abstract_t">Cousins DE, Taylor M, Lee V. The outcome of treatment of early syphilis with different benzathine penicillin regimens in HIV-infected and -uninfected patients. Int J STD AIDS 2012; 23:632.</a></li><li><a class="nounderline abstract_t">Ganesan A, Mesner O, Okulicz JF, et al. A single dose of benzathine penicillin G is as effective as multiple doses of benzathine penicillin G for the treatment of HIV-infected persons with early syphilis. Clin Infect Dis 2015; 60:653.</a></li><li><a class="nounderline abstract_t">Andrade R, Rodriguez-Barradas MC, Yasukawa K, et al. Single Dose Versus 3 Doses of Intramuscular Benzathine Penicillin for Early Syphilis in HIV: A Randomized Clinical Trial. Clin Infect Dis 2017; 64:759.</a></li><li class="breakAll">Dionne JA. One vs three weekly doses of benzathine penicillin G for treatment of early syphilis in persons with and without HIV: a multicenter randomized controlled trial. IDWeek 2023. Summary available at: https://www.ccjm.org/page/idweek-2023/benzathine-penicillin.</li><li><a class="nounderline abstract_t">Li J, Zheng HY. Early syphilis: serological treatment response to doxycycline/tetracycline versus benzathine penicillin. J Infect Dev Ctries 2014; 8:228.</a></li><li><a class="nounderline abstract_t">Ghanem KG, Erbelding EJ, Cheng WW, Rompalo AM. Doxycycline compared with benzathine penicillin for the treatment of early syphilis. Clin Infect Dis 2006; 42:e45.</a></li><li><a class="nounderline abstract_t">Wong T, Singh AE, De P. Primary syphilis: serological treatment response to doxycycline/tetracycline versus benzathine penicillin. Am J Med 2008; 121:903.</a></li><li><a class="nounderline abstract_t">Psomas KC, Brun M, Causse A, et al. Efficacy of ceftriaxone and doxycycline in the treatment of early syphilis. Med Mal Infect 2012; 42:15.</a></li><li><a class="nounderline abstract_t">Long CM, Klausner JD, Leon S, et al. Syphilis treatment and HIV infection in a population-based study of persons at high risk for sexually transmitted disease/HIV infection in Lima, Peru. Sex Transm Dis 2006; 33:151.</a></li><li><a class="nounderline abstract_t">Onoda Y. [Therapeutic effect of oral doxycycline on syphilis (author's transl]. Jpn J Antibiot 1980; 33:18.</a></li><li><a class="nounderline abstract_t">Harshan V, Jayakumar W. Doxycycline in early syphilis: a long term follow up. Indian J Dermatol 1982; 27:119.</a></li><li><a class="nounderline abstract_t">Wu H, Qi M, Wang H, et al. Efficacy of minocycline in the treatment of early syphilis. Int J STD AIDS 2021; 32:648.</a></li><li><a class="nounderline abstract_t">Smith NH, Musher DM, Huang DB, et al. Response of HIV-infected patients with asymptomatic syphilis to intensive intramuscular therapy with ceftriaxone or procaine penicillin. Int J STD AIDS 2004; 15:328.</a></li><li><a class="nounderline abstract_t">Spornraft-Ragaller P, Abraham S, Lueck C, Meurer M. Response of HIV-infected patients with syphilis to therapy with penicillin or intravenous ceftriaxone. Eur J Med Res 2011; 16:47.</a></li><li><a class="nounderline abstract_t">Cao Y, Su X, Wang Q, et al. A Multicenter Study Evaluating Ceftriaxone and Benzathine Penicillin G as Treatment Agents for Early Syphilis in Jiangsu, China. Clin Infect Dis 2017; 65:1683.</a></li><li><a class="nounderline abstract_t">Tanizaki R, Nishijima T, Aoki T, et al. High-dose oral amoxicillin plus probenecid is highly effective for syphilis in patients with HIV infection. Clin Infect Dis 2015; 61:177.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Syphilis (Treponema pallidum) 2018 Case Definition. https://ndc.services.cdc.gov/case-definitions/syphilis-2018/ (Accessed on June 17, 2021).</li><li><a class="nounderline abstract_t">Ghanem KG. Management of Adult Syphilis: Key Questions to Inform the 2015 Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines. Clin Infect Dis 2015; 61 Suppl 8:S818.</a></li><li><a class="nounderline abstract_t">Hook EW 3rd, Marra CM. Acquired syphilis in adults. N Engl J Med 1992; 326:1060.</a></li><li><a class="nounderline abstract_t">Augenbraun MH. Treatment of syphilis 2001: nonpregnant adults. Clin Infect Dis 2002; 35:S187.</a></li><li><a class="nounderline abstract_t">Masege SD, Karstaedt A. A rare case of a chronic syphilitic gumma in a man infected with human immunodeficiency virus. J Laryngol Otol 2014; 128:557.</a></li><li><a class="nounderline abstract_t">Reschke R, Kunz M, Ziemer M. Gummatous Cutaneous Syphilis. Dtsch Arztebl Int 2022; 119:457.</a></li><li><a class="nounderline abstract_t">Whiting C, Schwartzman G, Khachemoune A. Syphilis in Dermatology: Recognition and Management. Am J Clin Dermatol 2023; 24:287.</a></li><li><a class="nounderline abstract_t">Polnikorn N, Witoonpanich R, Vorachit M, et al. Penicillin concentrations in cerebrospinal fluid after different treatment regimens for syphilis. Br J Vener Dis 1980; 56:363.</a></li><li><a class="nounderline abstract_t">Gordon SM, Eaton ME, George R, et al. The response of symptomatic neurosyphilis to high-dose intravenous penicillin G in patients with human immunodeficiency virus infection. N Engl J Med 1994; 331:1469.</a></li><li><a class="nounderline abstract_t">Walter T, Lebouche B, Miailhes P, et al. Symptomatic relapse of neurologic syphilis after benzathine penicillin G therapy for primary or secondary syphilis in HIV-infected patients. Clin Infect Dis 2006; 43:787.</a></li><li><a class="nounderline abstract_t">Bettuzzi T, Jourdes A, Robineau O, et al. Ceftriaxone compared with benzylpenicillin in the treatment of neurosyphilis in France: a retrospective multicentre study. Lancet Infect Dis 2021; 21:1441.</a></li><li><a class="nounderline abstract_t">Shann S, Wilson J. Treatment of neurosyphilis with ceftriaxone. Sex Transm Infect 2003; 79:415.</a></li><li><a class="nounderline abstract_t">Yim CW, Flynn NM, Fitzgerald FT. Penetration of oral doxycycline into the cerebrospinal fluid of patients with latent or neurosyphilis. Antimicrob Agents Chemother 1985; 28:347.</a></li><li><a class="nounderline abstract_t">Dunaway SB, Maxwell CL, Tantalo LC, et al. Neurosyphilis Treatment Outcomes After Intravenous Penicillin G Versus Intramuscular Procaine Penicillin Plus Oral Probenecid. Clin Infect Dis 2020; 71:267.</a></li><li><a class="nounderline abstract_t">Yang CJ, Lee NY, Lin YH, et al. Jarisch-Herxheimer reaction after penicillin therapy among patients with syphilis in the era of the hiv infection epidemic: incidence and risk factors. Clin Infect Dis 2010; 51:976.</a></li><li><a class="nounderline abstract_t">Butler T. The Jarisch-Herxheimer Reaction After Antibiotic Treatment of Spirochetal Infections: A Review of Recent Cases and Our Understanding of Pathogenesis. Am J Trop Med Hyg 2017; 96:46.</a></li><li><a class="nounderline abstract_t">Butler T, Aikawa M, Habte-Michael A, Wallace C. Phagocytosis of Borrelia recurrentis by blood polymorphonuclear leukocytes is enhanced by antibiotic treatment. Infect Immun 1980; 28:1009.</a></li><li><a class="nounderline abstract_t">Pound MW, May DB. Proposed mechanisms and preventative options of Jarisch-Herxheimer reactions. J Clin Pharm Ther 2005; 30:291.</a></li><li><a class="nounderline abstract_t">Romanowski B, Sutherland R, Fick GH, et al. Serologic response to treatment of infectious syphilis. Ann Intern Med 1991; 114:1005.</a></li><li><a class="nounderline abstract_t">Augenbraun M, Rolfs R, Johnson R, et al. Treponemal specific tests for the serodiagnosis of syphilis. Syphilis and HIV Study Group. Sex Transm Dis 1998; 25:549.</a></li><li><a class="nounderline abstract_t">Seña AC, Zhang XH, Li T, et al. A systematic review of syphilis serological treatment outcomes in HIV-infected and HIV-uninfected persons: rethinking the significance of serological non-responsiveness and the serofast state after therapy. BMC Infect Dis 2015; 15:479.</a></li><li><a class="nounderline abstract_t">Fiumara NJ. Serologic responses to treatment of 128 patients with late latent syphilis. Sex Transm Dis 1979; 6:243.</a></li><li><a class="nounderline abstract_t">Pandey K, Fairley CK, Chen MY, et al. Changes in the Syphilis Rapid Plasma Reagin Titer Between Diagnosis and Treatment. Clin Infect Dis 2023; 76:795.</a></li><li><a class="nounderline abstract_t">Atsawawaranunt K, Kittiyaowamarn R, Phonrat B, et al. Time to Serological Cure and Associated Factors Among Syphilis Patients With and Without HIV in a Sexually Transmitted Infections Center, Thailand. Sex Transm Dis 2020; 47:283.</a></li></ol></div><div id="topicVersionRevision">Topic 7597 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34292926" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Sexually Transmitted Infections Treatment Guidelines, 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25387188" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Treatment of syphilis: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13296652" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Inoculation syphilis in human volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13296652" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Inoculation syphilis in human volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15758893" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Inadvertent use of Bicillin C-R to treat syphilis infection--Los Angeles, California, 1999-2004.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15758893" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Inadvertent use of Bicillin C-R to treat syphilis infection--Los Angeles, California, 1999-2004.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33640982" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Clinical Efficacy of Cefixime for the Treatment of Early Syphilis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16177249" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Single-dose azithromycin versus penicillin G benzathine for the treatment of early syphilis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20402591" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A phase III equivalence trial of azithromycin versus benzathine penicillin for treatment of early syphilis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20402591" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A phase III equivalence trial of azithromycin versus benzathine penicillin for treatment of early syphilis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19583516" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Macrolide resistance and molecular types of Treponema pallidum causing primary syphilis in Shanghai, China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19901863" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Evaluation of azithromycin resistance in Treponema pallidum specimens from Madagascar.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17109351" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Antibiotic selection may contribute to increases in macrolide-resistant Treponema pallidum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17109351" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Antibiotic selection may contribute to increases in macrolide-resistant Treponema pallidum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/795799" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Biopharmacology of syphilotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/789927" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Persistence of Treponema pallidum following penicillin G therapy. Report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9235493" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection. The Syphilis and HIV Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9235493" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection. The Syphilis and HIV Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7890932" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Neurosyphilis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7890932" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Neurosyphilis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23033515" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The outcome of treatment of early syphilis with different benzathine penicillin regimens in HIV-infected and -uninfected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25389249" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A single dose of benzathine penicillin G is as effective as multiple doses of benzathine penicillin G for the treatment of HIV-infected persons with early syphilis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28200045" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Single Dose Versus 3 Doses of Intramuscular Benzathine Penicillin for Early Syphilis in HIV: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28200045" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Single Dose Versus 3 Doses of Intramuscular Benzathine Penicillin for Early Syphilis in HIV: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24518634" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Early syphilis: serological treatment response to doxycycline/tetracycline versus benzathine penicillin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16477545" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Doxycycline compared with benzathine penicillin for the treatment of early syphilis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18823862" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Primary syphilis: serological treatment response to doxycycline/tetracycline versus benzathine penicillin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22119040" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Efficacy of ceftriaxone and doxycycline in the treatment of early syphilis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16508525" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Syphilis treatment and HIV infection in a population-based study of persons at high risk for sexually transmitted disease/HIV infection in Lima, Peru.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7373850" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : [Therapeutic effect of oral doxycycline on syphilis (author's transl].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7141473" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Doxycycline in early syphilis: a long term follow up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33496202" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Efficacy of minocycline in the treatment of early syphilis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15117503" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Response of HIV-infected patients with asymptomatic syphilis to intensive intramuscular therapy with ceftriaxone or procaine penicillin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21463980" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Response of HIV-infected patients with syphilis to therapy with penicillin or intravenous ceftriaxone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29020150" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : A Multicenter Study Evaluating Ceftriaxone and Benzathine Penicillin G as Treatment Agents for Early Syphilis in Jiangsu, China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25829004" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : High-dose oral amoxicillin plus probenecid is highly effective for syphilis in patients with HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25829004" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : High-dose oral amoxicillin plus probenecid is highly effective for syphilis in patients with HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26602620" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Management of Adult Syphilis: Key Questions to Inform the 2015 Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1549153" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Acquired syphilis in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12353205" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Treatment of syphilis 2001: nonpregnant adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24909596" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : A rare case of a chronic syphilitic gumma in a man infected with human immunodeficiency virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36321683" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Gummatous Cutaneous Syphilis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36689103" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Syphilis in Dermatology: Recognition and Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7448578" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Penicillin concentrations in cerebrospinal fluid after different treatment regimens for syphilis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7969296" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The response of symptomatic neurosyphilis to high-dose intravenous penicillin G in patients with human immunodeficiency virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16912958" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Symptomatic relapse of neurologic syphilis after benzathine penicillin G therapy for primary or secondary syphilis in HIV-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34051142" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Ceftriaxone compared with benzylpenicillin in the treatment of neurosyphilis in France: a retrospective multicentre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14573840" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Treatment of neurosyphilis with ceftriaxone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3834836" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Penetration of oral doxycycline into the cerebrospinal fluid of patients with latent or neurosyphilis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31504293" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Neurosyphilis Treatment Outcomes After Intravenous Penicillin G Versus Intramuscular Procaine Penicillin Plus Oral Probenecid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20825309" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Jarisch-Herxheimer reaction after penicillin therapy among patients with syphilis in the era of the hiv infection epidemic: incidence and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28077740" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The Jarisch-Herxheimer Reaction After Antibiotic Treatment of Spirochetal Infections: A Review of Recent Cases and Our Understanding of Pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7399684" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Phagocytosis of Borrelia recurrentis by blood polymorphonuclear leukocytes is enhanced by antibiotic treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15896248" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Proposed mechanisms and preventative options of Jarisch-Herxheimer reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2029095" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Serologic response to treatment of infectious syphilis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9858352" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Treponemal specific tests for the serodiagnosis of syphilis. Syphilis and HIV Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26511465" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : A systematic review of syphilis serological treatment outcomes in HIV-infected and HIV-uninfected persons: rethinking the significance of serological non-responsiveness and the serofast state after therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/531723" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Serologic responses to treatment of 128 patients with late latent syphilis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36285535" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Changes in the Syphilis Rapid Plasma Reagin Titer Between Diagnosis and Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32149964" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Time to Serological Cure and Associated Factors Among Syphilis Patients With and Without HIV in a Sexually Transmitted Infections Center, Thailand.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
